Alpha Tau Medical Ltd. (DRTSW) — 6-K Filings

6-K Filings (42)

• Alpha Tau Medical to Present at J.P. Morgan Healthcare Conference — Dec 18, 2025 Risk: low
  Alpha Tau Medical Ltd. announced on December 18, 2025, that it will present at the J.P. Morgan 2026 Healthcare Conference. The company, headquartered in Jerusal
• 6-K Filing — Dec 9, 2025
• Alpha Tau Medical to Present Pancreatic Cancer Data at ASCO GI — Dec 4, 2025 Risk: low
  Alpha Tau Medical Ltd. announced on December 4, 2025, that two abstracts detailing their Alpha DaRT technology for pancreatic cancer will be presented at the 20
• Alpha Tau Medical Gets FDA Green Light for Prostate Cancer Trial — Dec 2, 2025 Risk: medium
  Alpha Tau Medical Ltd. announced on December 2, 2025, that it has received FDA approval to begin a trial for patients with locally recurrent prostate cancer. Th
• 6-K Filing — Nov 20, 2025
• Alpha Tau Medical Secures NH Radioactive Material License — Oct 21, 2025 Risk: low
  On October 21, 2025, Alpha Tau Medical Ltd. announced it received a radioactive material license for its new manufacturing facility in New Hampshire. This licen
• Alpha Tau Medical treats first patient in US pancreatic cancer trial — Sep 2, 2025 Risk: medium
  Alpha Tau Medical Ltd. announced on September 2, 2025, that it has successfully treated the first patient in its U.S. multi-center clinical trial for pancreatic
• Alpha Tau Medical to Attend 5 Investor Conferences in September — Aug 27, 2025 Risk: low
  Alpha Tau Medical Ltd. announced on August 27, 2025, that it will participate in five investor conferences throughout September 2025. The company, headquartered
• Alpha Tau Medical Ltd. Files Interim Financials — Aug 11, 2025 Risk: medium
  Alpha Tau Medical Ltd. filed a Form 6-K on August 11, 2025, reporting its interim consolidated financial statements as of June 30, 2025, and an accompanying ope
• Alpha Tau Medical Ltd. Elects Directors at Annual Meeting — Jun 17, 2025 Risk: low
  On June 17, 2025, Alpha Tau Medical Ltd. held its Annual General Meeting of Shareholders where shareholders approved the re-election of directors Alan Adler and
• Alpha Tau Medical to Present at Jefferies Healthcare Conference — May 28, 2025 Risk: low
  Alpha Tau Medical Ltd. announced on May 28, 2025, that it will present at the Jefferies Global Healthcare Conference. The company, headquartered in Jerusalem, I
• Alpha Tau Medical Reports Q1 2025 Results — May 19, 2025 Risk: low
  On May 19, 2025, Alpha Tau Medical Ltd. announced its first quarter 2025 financial results and provided a corporate update. The company filed a Form 6-K to repo
• Alpha Tau Medical Sets Annual Shareholder Meeting for June 17 — May 13, 2025 Risk: low
  Alpha Tau Medical Ltd. is holding its annual general meeting of shareholders on June 17, 2025, at 3:00 p.m. Israel time, at its headquarters in Jerusalem. The c
• Alpha Tau Medical Appoints Nadav Kidron to Board — May 12, 2025 Risk: low
  On May 12, 2025, Alpha Tau Medical Ltd. announced the appointment of Nadav Kidron to its Board of Directors. Kidron's appointment is detailed in a press release
• Alpha Tau Medical to Attend May Investor Conferences — May 6, 2025 Risk: low
  Alpha Tau Medical Ltd. announced on May 6, 2025, that it will participate in upcoming investor conferences during May. The company, headquartered in Jerusalem,
• Alpha Tau Medical Raises $28.2M in Direct Offering — Apr 28, 2025 Risk: medium
  On April 24, 2025, Alpha Tau Medical Ltd. entered into a share purchase agreement with Oramed Ltd. for a registered direct offering. The company will sell 14,11
• Alpha Tau Medical Gets FDA Green Light for Glioblastoma Trial — Apr 2, 2025 Risk: medium
  Alpha Tau Medical Ltd. announced on April 2, 2025, that it has received FDA approval to begin a trial for patients suffering from recurrent glioblastoma. This m
• Alpha Tau Medical to Attend March Investor Conferences — Feb 27, 2025 Risk: low
  Alpha Tau Medical Ltd. announced on February 27, 2025, that it will participate in upcoming investor conferences in March. The company is a medical device compa
• Alpha Tau Medical Achieves MDSAP Certification — Feb 24, 2025 Risk: low
  Alpha Tau Medical Ltd. announced on February 24, 2025, that it has received Medical Device Single Audit Program (MDSAP) certification. This certification is a s
• Alpha Tau Medical Gets FDA Approval for Pancreatic Cancer Trial Expansion — Feb 3, 2025 Risk: medium
  On February 3, 2025, Alpha Tau Medical Ltd. announced that the FDA has approved a supplement to their Investigational Device Exemption (IDE) to expand their pil
• Alpha Tau Medical Shares Clinical Trial Data Update — Jan 27, 2025 Risk: medium
  On January 27, 2025, Alpha Tau Medical Ltd. announced that cornerstone interim data from multiple clinical trials will be presented at their R&D Update Day. Thi
• Alpha Tau Medical to Present New Data at ASCO GI Symposium — Dec 18, 2024 Risk: low
  Alpha Tau Medical Ltd. announced on December 18, 2024, that it will present new data at the 2025 ASCO GI Symposium and at its upcoming R&D Update Day. The press
• Alpha Tau Medical Ltd. Elects New Directors — Dec 17, 2024 Risk: low
  On December 17, 2024, Alpha Tau Medical Ltd. held its Annual General Meeting of Shareholders. Shareholders approved the re-election of Michael Avruch and Uzi So
• Alpha Tau Medical to Present at J.P. Morgan Healthcare Conference — Dec 11, 2024 Risk: low
  Alpha Tau Medical Ltd. announced on December 11, 2024, that it will present at the 43rd Annual J.P. Morgan Healthcare Conference. The company, headquartered in
• Alpha Tau Medical to Present at Oncology Symposium — Dec 6, 2024 Risk: low
  Alpha Tau Medical Ltd. announced on December 6, 2024, that it will participate in Ladenburg's Oncology Innovators & Investors Symposium. The company, which deve
• Alpha Tau Medical Reports Q3 2024 Results — Nov 19, 2024 Risk: medium
  Alpha Tau Medical Ltd. announced its third quarter 2024 financial results and provided a corporate update via a press release on November 19, 2024. The filing i
• Alpha Tau Medical to Present at Healthcare Conferences — Nov 13, 2024 Risk: low
  Alpha Tau Medical Ltd. announced on November 13, 2024, that it will participate in two upcoming investor conferences: Citi's 2024 Global Healthcare Conference a
• Alpha Tau Medical Sets Shareholder Meeting for Dec 17 — Nov 12, 2024 Risk: low
  Alpha Tau Medical Ltd. is holding its annual general meeting of shareholders on December 17, 2024, at its headquarters in Jerusalem, Israel. The meeting will in
• Alpha Tau Medical Accepted into FDA TPLC Program — Oct 21, 2024 Risk: medium
  On October 21, 2024, Alpha Tau Medical Ltd. announced its acceptance into the FDA's Total Product Life Cycle (TPLC) Advisory Program. This program aims to accel
• Alpha Tau Medical Treats First Recurrent Lung Cancer Patient — Oct 10, 2024 Risk: medium
  On October 10, 2024, Alpha Tau Medical Ltd. announced it has treated the first patient with its innovative technology for recurrent lung cancer. This milestone
• Alpha Tau Medical Gets FDA IDE for cSCC Study — Sep 20, 2024 Risk: medium
  Alpha Tau Medical Ltd. announced on September 20, 2024, that it has received FDA approval for an Investigational Device Exemption (IDE) to begin a multi-center
• Alpha Tau Medical to Present at Multiple Investor Conferences — Aug 22, 2024 Risk: low
  Alpha Tau Medical Ltd. announced on August 22, 2024, that it will participate in four upcoming investor conferences: the H.C. Wainwright 26th Annual Global Inve
• Alpha Tau Medical Ltd. Files Interim Financials — Aug 14, 2024 Risk: low
  Alpha Tau Medical Ltd. filed a Form 6-K on August 14, 2024, reporting its interim consolidated financial statements as of June 30, 2024. The filing is a report
• Alpha Tau Medical Data Published in Cancers Journal — Jun 25, 2024 Risk: medium
  Alpha Tau Medical Ltd. announced on June 25, 2024, the publication of long-term safety and efficacy data for its superficial cancer treatment in the journal Can
• Alpha Tau Medical to Present at Jefferies Healthcare Conference — May 21, 2024 Risk: low
  Alpha Tau Medical Ltd. announced on May 21, 2024, that it will present at the Jefferies Global Healthcare Conference. The company, headquartered in Jerusalem, I
• Alpha Tau Medical Reports Q1 2024 Results — May 20, 2024 Risk: low
  Alpha Tau Medical Ltd. announced its first quarter 2024 financial results and provided a corporate update on May 20, 2024. The company is a foreign private issu
• Alpha Tau Treats First Liver Metastases Patient — May 13, 2024 Risk: medium
  On May 13, 2024, Alpha Tau Medical Ltd. announced the treatment of the first patient with liver metastases of colorectal cancer using its Alpha DaRT technology.
• Alpha Tau Medical Presents Pancreatic Cancer Preclinical Data — May 6, 2024 Risk: medium
  On May 6, 2024, Alpha Tau Medical Ltd. announced preclinical data presented at the ESTRO 2024 Congress in Glasgow. The data demonstrated an abscopal immune effe
• Alpha Tau Medical to Attend May Investor Conferences — May 1, 2024 Risk: low
  Alpha Tau Medical Ltd. announced on May 1, 2024, that it will participate in upcoming investor conferences during May. The company is a medical device firm focu
• Alpha Tau Medical to Present at Jefferies Radiopharma Summit — Mar 25, 2024 Risk: low
  On March 25, 2024, Alpha Tau Medical Ltd. announced its participation in the Jefferies Radiopharma Innovation Summit. The company, headquartered in Jerusalem, I
• Alpha Tau Medical Reports 2022 Financials — Mar 7, 2024 Risk: low
  Alpha Tau Medical Ltd. filed a Form 6-K on March 7, 2024, to report its full-year 2022 financial results and provide a corporate update. The filing includes a p
• Alpha Tau to Present at Barclays Global Healthcare Conference — Feb 26, 2024 Risk: low
  Alpha Tau Medical Ltd. announced on February 26, 2024, that it will participate in the Barclays 26th Annual Global Healthcare Conference. The company issued a p

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX